Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 3/20 | 0.65 |
| ▸ | ESR1 | P03372 | 2/20 | 0.65 |
| ▸ | TTR | P02766 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 6/20 | 0.56 |
| ▸ | ALOX15B | O15296 | 3/20 | 0.56 |
| ▸ | RARA | P10276 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | RARG | P13631 | 1/20 | 0.42 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 3/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19409317 | 0.92 | ESR2 (0.67) | ESR2ESR1TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL936521 | 0.84 | ESR2 (0.75) | ESR2ESR1TTRALOX15ALOX12 | |
| SCHEMBL31545514 | 0.82 | ESR1 (0.72) | ESR2ESR1TTRALOX15ALOX12 | |
| SCHEMBL17594509 | 0.82 | ESR2 (0.67) | ESR2ESR1TTRALOX15ALOX12 | |
| SCHEMBL14374112 | 0.81 | ESR2 (0.65) | ESR2ESR1TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL43648 | 0.80 | ESR2 (1.00) | ESR2ESR1TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL2002128 | 0.80 | ESR2 (1.00) | ESR2ESR1TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL29467332 | 0.80 | ESR2 (1.00) | ESR2ESR1TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL677723 | 0.80 | ESR2 (1.00) | ESR2ESR1TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL43647 | 0.80 | ESR2 (1.00) | ESR2ESR1TTRALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023126758-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2023-07-06 | — | — | WO | claimed |
| US-20230204604-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-06-29 | — | — | US | claimed |
| US-20220175851-A1 | COMPOSITIONS, METHODS FOR REGULATING UTERINE, PLACENTAL GROWTH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-09 | — | — | US | claimed |
| US-20210353611-A1 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-11-18 | — | — | US | claimed |
| US-11092591-B2 | Host and intestinal microbiota derived metabolomic blood plasma signature for prior radiation injury | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2021-08-17 | — | — | US | claimed |
| EP-3852759-A2 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | Yeda Research and Development Co. Ltd (IL) | 2021-07-28 | — | — | EP | claimed |
| CN-113038951-A | Method of treating amyotrophic lateral sclerosis | 耶达研究及发展有限公司 | 2021-06-25 | — | — | CN | claimed |
| US-20210088539-A1 | AUTOMATED SAMPLE QUALITY ASSESSMENT | METABOLON, INC. | 2021-03-25 | — | — | US | claimed |
| US-10890592-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2021-01-12 | — | — | US | claimed |
| WO-2020186161-A2 | COMPOSITIONS AND METHODS FOR REGULATING UTERINE AND PLACENTAL GROWTH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-17 | — | — | WO | claimed |
| WO-2020058979-A2 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2020-03-26 | — | — | WO | claimed |
| US-20170299573-A1 | HOST AND INTESTINAL MICROBIOTA DERIVED METABOLOMIC BLOOD PLASMA SIGNATURE FOR PRIOR RADIATION INJURY | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2017-10-19 | — | — | US | claimed |
| WO-2016081292-A1 | HOST AND INTESTINAL MICROBIOTA DERIVED METABOLOMIC BLOOD PLAMSA SIGNATURE FOR PRIOR RADIATION INJURY | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2016-05-26 | — | — | WO | claimed |
| CN-113038951-B | Method for treating amyotrophic lateral sclerosis | 耶达研究及发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2023229970-A1 | PET FOOD COMPOSITIONS COMPRISING BETA-1,3-1,6-GLUCAN AND POLYPHENOLIC ISOFLAVONOIDS | HILL'S PET NUTRITION, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230372386-A1 | Pet Food Compositions | HILL'S PET NUTRITION, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20140335131-A1 | PROBIOTIC PREVENTION AND TREATMENT OF COLON CANCER | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140065132-A1 | DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2014-03-06 | — | — | US | disclosed |
| WO-2014036182-A2 | DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-03-06 | — | — | WO | disclosed |
| WO-2011010103-A1 | METHODS AND USES | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353611-A1 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, OAT | ESR2 2316/4885ESR1 4304/4885TTR 356/4885 |
| US-20220175851-A1 | COMPOSITIONS, METHODS FOR REGULATING UTERINE, PLACENTAL GROWTH | PGF, FGR, VEGFA | ESR2 1663/4885ESR1 3524/4885TTR 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.